Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The miR-29b binding site on progranulin mRNA (GRN mRNA) is an evolutionarily conserved sequence located in the 3′ untranslated region (3′UTR) of the GRN transcript. This site serves as a docking region for microRNA-29b (miR-29b), a small non-coding RNA that downregulates GRN by binding to this specific 3′UTR sequence, thereby repressing translation or destabilizing the transcript. Disruption of this interaction by targeted antisense oligonucleotides can relieve miR-29b-mediated silencing and increase progranulin protein production, offering a potential therapeutic approach for conditions associated with progranulin deficiency such as frontotemporal dementia. The site itself is not a protein or classic receptor but rather an RNA regulatory element that mediates a critical step in the post-transcriptional control of gene expression[1][3][4][5].
Antisense oligonucleotides bind to the miR-29b binding site on GRN mRNA, preventing miR-29b from downregulating GRN and thus increasing progranulin protein translation[3][4][5] - This post-transcriptional interference relieves the suppression normally imposed by miR-29b on GRN mRNA[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on miR-29b binding site on progranulin mRNA (null).